Enliven Therapeutics (NASDAQ:ELVN) Shares Gap Up Following Analyst Upgrade

Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) gapped up prior to trading on Monday after Robert W. Baird raised their price target on the stock from $40.00 to $52.00. The stock had previously closed at $21.91, but opened at $23.38. Robert W. Baird currently has an outperform rating on the stock. Enliven Therapeutics shares last traded at $23.25, with a volume of 115,307 shares traded.

Other analysts have also recently issued research reports about the stock. The Goldman Sachs Group initiated coverage on shares of Enliven Therapeutics in a report on Monday. They set a "buy" rating and a $37.00 target price on the stock. Jones Trading lowered their price target on shares of Enliven Therapeutics from $36.00 to $27.00 and set a "buy" rating for the company in a research report on Friday, May 16th. Finally, HC Wainwright boosted their price objective on shares of Enliven Therapeutics from $39.00 to $40.00 and gave the stock a "buy" rating in a research note on Thursday, May 15th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of "Buy" and an average target price of $39.60.

Insider Activity

In other news, CEO Samuel Kintz sold 5,000 shares of the business's stock in a transaction on Thursday, April 17th. The stock was sold at an average price of $16.42, for a total value of $82,100.00. Following the completion of the transaction, the chief executive officer now owns 985,392 shares in the company, valued at $16,180,136.64. The trade was a 0.50% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, COO Anish Patel sold 6,667 shares of the business's stock in a transaction dated Monday, June 9th. The stock was sold at an average price of $20.34, for a total value of $135,606.78. Following the completion of the transaction, the chief operating officer now directly owns 303,309 shares of the company's stock, valued at approximately $6,169,305.06. This trade represents a 2.15% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 88,611 shares of company stock worth $1,695,914 over the last 90 days. 25.90% of the stock is currently owned by insiders.

Institutional Trading of Enliven Therapeutics

Hedge funds have recently bought and sold shares of the company. Charles Schwab Investment Management Inc. lifted its stake in shares of Enliven Therapeutics by 2.6% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 261,888 shares of the company's stock worth $5,892,000 after purchasing an additional 6,611 shares during the period. Swiss National Bank increased its stake in shares of Enliven Therapeutics by 13.9% in the 4th quarter. Swiss National Bank now owns 41,873 shares of the company's stock worth $942,000 after purchasing an additional 5,100 shares in the last quarter. Intech Investment Management LLC purchased a new position in Enliven Therapeutics during the fourth quarter valued at $367,000. KLP Kapitalforvaltning AS bought a new stake in Enliven Therapeutics during the fourth quarter valued at about $97,000. Finally, Vanguard Group Inc. raised its stake in shares of Enliven Therapeutics by 2.9% in the fourth quarter. Vanguard Group Inc. now owns 1,975,655 shares of the company's stock worth $44,452,000 after buying an additional 55,283 shares during the period. Hedge funds and other institutional investors own 95.08% of the company's stock.

Enliven Therapeutics Trading Down 1.1%

The stock has a 50 day moving average of $18.65 and a 200-day moving average of $20.61. The company has a market capitalization of $1.06 billion, a P/E ratio of -11.23 and a beta of 0.79.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.06). As a group, sell-side analysts expect that Enliven Therapeutics, Inc. will post -1.95 EPS for the current fiscal year.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.